XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
September 30, 2021December 31, 2020
Current pharma contract assets (1)
$1,903 $1,643 
Long-term pharma contract assets (2)
248 290 
Total pharma contract assets$2,151 $1,933 
Current pharma capitalized commissions (1)
$126 $185 
Long-term pharma capitalized commissions (2)
953 970 
Total pharma capitalized commissions$1,079 $1,155 
Current pharma contract liabilities$5,278 $4,029 
Long-term pharma contract liabilities (3)
932 712 
Total pharma contract liabilities$6,210 $4,741 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Clinical Services:
    Client direct billing$64,195 $72,896 $188,040 $172,431 
    Commercial Insurance19,539 19,218 58,642 56,360 
    Medicare and Medicaid18,295 16,460 52,929 46,484 
    Self-Pay198 159 508 324 
Total Clinical Services $102,227 $108,733 $300,119 $275,599 
Pharma Services:19,113 16,711 58,478 42,852 
Total Revenue$121,340 $125,444 $358,597 $318,451